Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs
Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

Type 2 diabetes
Ehtasham Ahmad, Soo Lim, Roberta Lamptey, et al.
The Lancet (2022) Vol. 400, Iss. 10365, pp. 1803-1820
Closed Access | Times Cited: 563
Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
Milton Packer
Circulation (2022) Vol. 146, Iss. 18, pp. 1383-1405
Open Access | Times Cited: 253
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Chengxu Ma, Xiaoni Ma, Conghui Guan, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 229
Direct cardiac effects of SGLT2 inhibitors
Sha Chen, Ruben Coronel, Markus W. Hollmann, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 107
The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
Dario Giugliano, Miriam Longo, Simona Signoriello, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 99
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism
Milton Packer
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 443-462
Open Access | Times Cited: 96
Management of diabesity: Current concepts
Maria Michaelidou, Joseph M. Pappachan, Mohammad Sadiq Jeeyavudeen
World Journal of Diabetes (2023) Vol. 14, Iss. 4, pp. 396-411
Open Access | Times Cited: 50
Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes
Milton Packer, Christopher S. Wilcox, Jeffrey M. Testani
Circulation (2023) Vol. 148, Iss. 4, pp. 354-372
Open Access | Times Cited: 49
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 53
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Melanie J. Davies, Heinz Drexel, François R. Jornayvaz, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 44
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
Bains Jasleen, Gupta K Vishal, Malepati Sameera, et al.
Cureus (2023)
Open Access | Times Cited: 37
Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium–glucose cotransporter 2 inhibitors
Milton Packer
European Heart Journal (2023) Vol. 44, Iss. 48, pp. 5027-5035
Open Access | Times Cited: 34
Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus
Ruining Zhang, Qingxing Xie, Xi Lu, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 10
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
André Scheen, Fabrice Bonnet
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101419-101419
Open Access | Times Cited: 20
Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia
Milton Packer
American Journal of Nephrology (2023) Vol. 55, Iss. 2, pp. 255-259
Open Access | Times Cited: 19
Diabetes mellitus treatment
Chin Meng Khoo
Elsevier eBooks (2023), pp. 417-427
Closed Access | Times Cited: 17
Dicarbonyl Stress in Diabetic Vascular Disease
Bernd Stratmann
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 11, pp. 6186-6186
Open Access | Times Cited: 24
Research progress on the effects of novel hypoglycemic drugs in diabetes combined with myocardial ischemia/reperfusion injury
Tiangui Yang, Daqing Zhang
Ageing Research Reviews (2023) Vol. 86, pp. 101884-101884
Closed Access | Times Cited: 13
Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis
Ahmed E. Ali, Muhammad S Mazroua, Mariam ElSaban, et al.
Global Heart (2023) Vol. 18, Iss. 1, pp. 45-45
Open Access | Times Cited: 11
Empagliflozin rescues lifespan and liver senescence in naturally aged mice
Jiangchuan Long, Ziyu Ren, Yaqian Duan, et al.
GeroScience (2024) Vol. 46, Iss. 5, pp. 4969-4986
Open Access | Times Cited: 4
Update on the Efficacy and Safety of Sodium–Glucose Co-Transporter 2 Inhibitors in Patients with Chronic Diseases: A Systematic Review and Meta-Analysis
I-Chia Liang, Hsun-Hao Chang, Yu-Jou Lai, et al.
Medicina (2025) Vol. 61, Iss. 2, pp. 202-202
Open Access
Identification of lipid metabolism-related genes in dapagliflozin treated rats with diabetic cardiomyopathy by bioinformatics
Xun Huang, Yunhong Wang, Rong Wan, et al.
Frontiers in Endocrinology (2025) Vol. 16
Open Access
Obesity accelerates cardiovascular ageing
Celia Rupérez, Frank Madeo, Rafael de Cabo, et al.
European Heart Journal (2025)
Open Access
Sotagliflozin provides additional benefits for high-fat diet-induced cardiac inflammatory injury by extra inhibiting P38MAPK and JNK
Jian-Chao Luo, Le-hao Jin, Yun-shan Zhong, et al.
International Immunopharmacology (2025) Vol. 155, pp. 114631-114631
Closed Access
Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches
Dimitra Vasdeki, Theocharis Koufakis, Georgios Tsamos, et al.
Nutrients (2022) Vol. 14, Iss. 22, pp. 4801-4801
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top